Literature DB >> 21478021

Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes.

Neil Vasdev1, Peter N Dorff, James P O'Neil, Frederick T Chin, Stephen Hanrahan, Henry F VanBrocklin.   

Abstract

Epidermal growth factor receptors (EGFR), upregulated in many tumor types, have been a target for therapeutic development and molecular imaging. The objective of this study was to evaluate the distribution and metabolic characteristics of fluorine-18 labeled anilinoquinazolines as potential imaging agents for EGFR tyrosine kinase expression. Fluorine-18 labeled fluoronitrobenzenes were prepared by reaction of potassium cryptand [(18)F]fluoride with 1,2- and 1,4-dinitrobenzenes, and 3-nitro-N,N,N-trimethylanilinium triflate in 5min. Decay-corrected radiochemical yields of [(18)F]fluoride incorporation into the nitro-aromatic compounds were 81±2%, 44±4% and 77±5% (n=3-5) for the 2-, 3- and 4-fluoro isomers, respectively. Sodium borohydride reduction to the corresponding [(18)F]fluoroanilines was achieved with greater than 80% conversion in 5min. Coupling of [(18)F]fluoroaniline-hydrochlorides to 6,7-dimethoxy-4-chloro-quinazoline gave the corresponding 6,7-dimethoxy-4-(2-, 3- and 4-[(18)F]fluoroanilino)quinazolines in 31±5%, 17±2% and 55±2% radiochemical yield, respectively, while coupling to the 6,7-diethoxy-4-chloro-quinazoline produced 6,7-diethoxy-4-(2-, 3- and 4-[(18)F]fluoroanilino)quinazolines in 19±6%, 9±3% and 36±6% radiochemical yield, respectively, in 90min to end of synthesis from [(18)F]fluoride. Biodistribution of 2- and 4-[(18)F]fluoroanilinoquinazolines was conducted in tumor-bearing mice (MDA-MB-435 and MDA-MB-468 xenografts). Low tumor uptake (<1% injected dose per gram (ID/g) of tissue up to 3h postinjection of the radiotracers) was observed. High bone uptake (5-15% ID/g) was noted with the 4-[(18)F]fluoroanilinoquinazolines. The metabolic stabilities of radiolabeled quinazolines were further evaluated by incubation with human female cryopreserved isolated hepatocytes. Rapid degeneration of the 4-fluoro-substituted compounds to baseline polar metabolites was observed by radio-TLC, whereas, the 2- and 3-[(18)F]fluoroaniline derivatives were significantly more stable, up to 2h, corroborating the in vivo biodistribution studies. para-Substituted [(18)F]fluoroanilines, a common structural motif in radiopharmaceuticals, are highly susceptible to metabolic degradation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478021      PMCID: PMC3099137          DOI: 10.1016/j.bmc.2011.03.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  31 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer.

Authors:  Eyal Mishani; Aviv Hagooly
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

Review 3.  Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.

Authors:  Vladimir Tolmachev; Sharon Stone-Elander; Anna Orlova
Journal:  Lancet Oncol       Date:  2010-07-26       Impact factor: 41.316

Review 4.  PET radiotracers: crossing the blood-brain barrier and surviving metabolism.

Authors:  Victor W Pike
Journal:  Trends Pharmacol Sci       Date:  2009-07-16       Impact factor: 14.819

Review 5.  Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography.

Authors:  Juri G Gelovani
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

Review 6.  Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer.

Authors:  M A Pantaleo; M Nannini; A Maleddu; S Fanti; C Nanni; S Boschi; F Lodi; G Nicoletti; L Landuzzi; P L Lollini; G Biasco
Journal:  Ann Oncol       Date:  2008-10-07       Impact factor: 32.976

Review 7.  Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR).

Authors:  Eyal Mishani; Galith Abourbeh
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 8.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Authors:  Jörg Thomas Hartmann; Michael Haap; Hans-Georg Kopp; Hans-Peter Lipp
Journal:  Curr Drug Metab       Date:  2009-06       Impact factor: 3.731

9.  PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans.

Authors:  Ningbo Liu; Minghuan Li; Xiaoyu Li; Xue Meng; Guoren Yang; Shuqiang Zhao; Yi Yang; Li Ma; Zheng Fu; Jinming Yu
Journal:  J Nucl Med       Date:  2009-01-21       Impact factor: 10.057

Review 10.  Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT.

Authors:  Justin W Hicks; Henry F VanBrocklin; Alan A Wilson; Sylvain Houle; Neil Vasdev
Journal:  Molecules       Date:  2010-11-15       Impact factor: 4.411

View more
  5 in total

1.  Fluorine bonding enhances the energetics of protein-lipid binding in the gas phase.

Authors:  Lan Liu; Nobar Jalili; Alyson Baergen; Simon Ng; Justin Bailey; Ratmir Derda; John S Klassen
Journal:  J Am Soc Mass Spectrom       Date:  2014-05       Impact factor: 3.109

2.  Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain.

Authors:  J Ryan Petrulli; Jenna M Sullivan; Ming-Qiang Zheng; Daniel C Bennett; Jonathan Charest; Yiyun Huang; Evan D Morris; Joseph N Contessa
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.

Authors:  Satish K Chitneni; Zachary J Reitman; Rebecca Spicehandler; David M Gooden; Hai Yan; Michael R Zalutsky
Journal:  Bioorg Med Chem Lett       Date:  2018-01-12       Impact factor: 2.823

4.  Total Radiosynthesis: Thinking outside "the box".

Authors:  Steven H Liang; Neil Vasdev
Journal:  Aust J Chem       Date:  2015-08-28       Impact factor: 1.321

5.  Controlled Release of Pyrimidine Compound Using Polymeric Coated ZIF-8 Metal-Organic Framework as Glucagon-Like Peptide-1 Receptor Agonist Carrier.

Authors:  Shaikha S AlNeyadi; Naheed Amir; Mohammad A Ghattas; Noor Atatreh; Shaikha S Alketbi; Ruba Al Ajeil; Abdu Adem
Journal:  Molecules       Date:  2020-09-20       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.